Publications by authors named "F Dahlke"
Article Synopsis
- Evobrutinib, a BTK inhibitor, was evaluated for safety and efficacy against teriflunomide in treating relapsing multiple sclerosis in two phase 3 trials involving nearly 2,300 participants across 52 countries.
- Participants aged 18-55 with specific disability scores were randomly assigned to receive either evobrutinib or teriflunomide, with both studies designed as double-blind to avoid bias among participants and researchers.
- The primary endpoint was the annualized relapse rate over 156 weeks, with data collected from June 2020 to October 2023, showing that 66-67% of the participants were female across the trials.
Amphibians and fishes play a central role in shaping the structure and function of freshwater environments. These organisms have a limited capacity to disperse across different habitats and the thermal buffer offered by freshwater systems is small. Understanding determinants and patterns of their physiological sensitivity across life history is, therefore, imperative to predicting the impacts of climate change in freshwater systems.
View Article and Find Full Text PDFBackground: Upper extremity function (UEF) is often compromised in multiple sclerosis (MS), although its importance is regularly underrecognized relative to ambulation. We explored the concurrent presence of impairment in UEF and ambulation by examining various aspects of UEF across different levels of ambulation.
Methods: The cohort consisted of 247 patients with clinically definite MS or clinically isolated syndrome according to the revised 2010 McDonald criteria.
Article Synopsis
- - Maladjusted immune responses in COVID-19 can lead to severe issues like cytokine release syndrome and respiratory distress, signaling the need for effective treatments.
- - Sphingosine-1-phosphate (S1P) and its receptors play a vital role in keeping blood vessel integrity and regulating immune cell movements, potentially improving outcomes in severe COVID-19 cases.
- - The use of S1PR modulators like fingolimod and siponimod shows promise in reducing inflammation and could be beneficial for critically ill COVID-19 patients experiencing hyperinflammation.